Great summary re: avoiding false positive PSMA pitfalls from Irene Burger #APCCCDiagnostics25

Reflections on the demand for PSMA- and SSTR-targeted radiopharmaceutical therapies: Why we were wrong (and why we will be right eventually). ow.ly/T40950UYrU2 #RPTherapy #NuclearMedicine #Theranostics Jeremie Calais Lisa Bodei, MD, PhD Johannes Czernin

Response and progression criteria for PSMA PET: Imaging #ProstateCancer outcomes. Wolfgang Fendler, MD Uni Duisburg-Essen @unidue.bsky.social joins Oliver Sartor, MD Mayo Clinic, to discuss the evolving role of PSMA PET imaging in assessing treatment response and progression in prostate cancer. #WatchNow >

PSMA PET must be used for clinical trial readouts and by regulators. Is PCWG4 coming? Mike Morris will tell us if and how!

ONE WEEK until the 2025 PSMA & Beyond Conference! Space is limited so register soon! If you cannot join us in LA, virtual registration is available for only $50! bit.ly/psmabeyond

Kinetics of PSMA PET signal after radiotherapy in 217 prostate cancer lesions: It takes multiple months for the uptake to decrease (> 6 months). Beware of "pseudo-progression" on PSMA PET performed shortly after RT. Radiotherapy & Oncology Masatoshi Hotta UCLA sciencedirect.com/science/articl…

Looking forward to seeing everyone at the PSMA & Beyond Conference starting Friday at UCLA. We have sold out all of our in person availability! If you haven’t registered, you can still join virtually (cvent.me/82PXbr).

Exciting 177Lu-PSMA-617 has been approved by the FDA for use prior to chemotherapy based on the PSMAfore results. Perfect timing, during day 1 of the PSMA and Beyond Conference! bit.ly/42lfdlz

Michael Hofman presents at 2025 PSMA & Beyond Conference UCLA UC San Francisco Prostate Cancer Foundation ... Impressive attendance! Thanks to organisers: Thomas Hope Jeremie Calais Johannes Czernin UroToday.com Don't miss our next webinar: Link.prostic.org/webinar

BIG NEWS! Yesterday the FDA expanded the indication for lutetium-177 vipivotide tetraxetan (Pluvicto), allowing its use before taxane-based chemotherapy. The new approval triples Pluvicto’s eligible patient population. More here: fda.gov/drugs/resource…

WHAT A FLIGHT! On our first flight today we got to a clean liftoff, 30sec of flight, and didn't blow up the pad in the meantime. Super proud of our team Isar Aerospace

Lot of content, Great Presentations and discussions during these 2 days ! Thank you all !! Jeremie Calais Thomas Hope PCF Science UCLA UC San Francisco UroToday.com Johannes Czernin

FDA expands Pluvicto’s metastatic castration-resistant prostate cancer indication fda.gov/drugs/resource… The U.S. FDA 🇺🇸expanded the indication for lutetium Lu 177 vipivotide tetraxetan to include adults with PSMA-positive metastatic castration-resistant #ProstateCancer (mCRPC)

The 63rd Annual Meeting of the German Society for Nuclear Medicine (Deutsche Gesellschaft für Nuklearmedizine - DGN) kicked off yesterday in Bremen! 🇩🇪 If you're attending, stop by the EANM desk! 👋

Huge congratulations to Michael Hofman for receiving the prestigious 2025 The Royal Australasian College of Physicians Eric Sussman Prize, presented for the best contribution to the knowledge of any branch of internal medicine, adult or pediatrics, for his work in prostate theranostics. racp.edu.au/news-and-event…

. GE HealthCare Unveils Enhanced LesionID Pro at #SNMMI25 Conference diagnosticimaging.com/view/ge-health… American College of Radiology ARRS RSNA SNMMI Yale Department of Radiology & Biomedical Imaging Penn Radiology Johns Hopkins Radiology Ohio State Radiology UAB Radiology Winship Cancer Institute of Emory University Montefiore Radiology #radiology #RadRes

How about Lead-212? Presentation by David Pattison, MBBS, MPH, FRACP, highlighting 212Pb as a promising alpha-emitter for PSMA-targeted therapy in #mCRPC—offering potent tumor kill, short-range precision, manageable safety, and even immune activation potential.. #SNMMI25 written

@SNMMI25 Dr Andrew Scott gave Henry Wagner lecture and honored Dr Saul Hertz as founder I-131 therapy and the beginning of our Industrial Revolution now occuring in radiopharmaceutical development and theranostics

Evaluation of PSMA PET/CT derived predictors for treatment response to 177Lu-PSMA-617: Results from The U.S. Expanded-Access Program. Presented by Koichiro Kimura, MD UCLA. #SNMMI25 written coverage by Zach Klaassen Georgia Cancer Center > bit.ly/4ndhjwx #SNMMI2025 SNMMI

Tumor Sink Effect in 68Ga-PSMA-11 PET: Myth or Reality? "Tumor sequestration affects 68Ga-PSMA biodistribution in normal organs. Patients with a very high tumor load showed a significantly lower uptake of 68Ga-PSMA in normal organs, confirming a tumor sink effect. " An